Brief: Hyloris Pharmaceuticals H1 Total Revenue Up At EUR 1.23 Mln

Hyloris Pharmaceuticals SA

01/09/2022 06:15

Sept 1 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * HYLORIS PHARMACEUTICALS REPORTS 2022 HALF-YEAR RESULTS AND
PROVIDES CORPORATE UPDATE
    * ON TRACK TO BROADEN PRODUCT PIPELINE TO MEET A TARGET
PORTFOLIO
OF 30 PROGRAMS BY 2024
    * H1 EUR 57,687 MILLION IN CASH AND CASH EQUIVALENTS
    * REMAINS WELL-CAPITALIZED TO ADVANCE ALL VALUE-ADDED ASSETS
AND
EXECUTE ON THIS ACCRETIVE BUSINESS STRATEGY TO EXPAND ITS
PORTFOLIO TO 30 PRODUCT CANDIDATES AND MARKETED PRODUCTS BY 2024
    * CONTINUED COMMERCIAL ROLLOUT OF SOTALOL IV IN US AND
MAXIGESIC®
IV
    * H1 TOTAL REVENUES EUR 1.23 MLN, NET LOSS EUR 4.9 MLN,
OPERATING
LOSS EUR 4.9 MLN

Source text for Eikon:  ID:nGNEc3dMZB 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))